title: Should atypical lymphocytes and plasma cells in well patients with psoriasis on cyclosporin cause concern?
authors.forename: B D
authors.initials: BD
authors.lastname: Edwards
authors.forename: F W
authors.initials: FW
authors.lastname: Ballardie
authors.forename: D J
authors.initials: DJ
authors.lastname: Morris
authors.forename: J B
authors.initials: JB
authors.lastname: O'Driscoll
authors.forename: R J
authors.initials: RJ
authors.lastname: Chalmers
mesh_terms: D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D003587:Cytomegalovirus / Q000187:drug effects; D004854:Herpesvirus 4, Human / Q000187:drug effects; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects* / Q000473:pathology*; D008223:Lymphoma / Q000139:chemically induced; D010950:Plasma Cells / Q000187:drug effects* / Q000473:pathology*; D011565:Psoriasis / Q000188:drug therapy*; D012307:Risk Factors; D014775:Virus Activation / Q000187:drug effects
chemical_list: D016572:Cyclosporine